Isoquercetin is suggested to suppress reactive oxygen species (ROS) and, through the regulation of lactate dehydrogenase (LDH) release in hippocampal neurons, the extracellular signaling-regulated expression of protein kinase 1 and 2 (ERK1/2-mediated) and nuclear factor erythroid 2-associated factor 2 (Nrf2) provides a useful support for the mitigation of neurodegenerative diseases, including Parkinson's disease and Alzheimer's disease. It acts as a selective SIRT6 activator, binding only to the SIRT6-selective acyl-binding channel due to its ability to discriminate between an alternative and the SIRT6-selective acyl-binding channel. Furthermore, a selectivity study of the isoform Isoquercetin revealed that the bulky sugar moiety harbors the acyl channel of SIRT6s. Isoquercetin has been reported to exhibit cytotoxic/anticancer activity by inhibiting protein kinase B phosphorylation. Thus, the surviving protein activates caspases and reduces anti-apoptotic proteins, namely Bcl-2 and Mcl-1.

PUBLICATIONS ON THE SUBJECT:

** Exp Ther Med. 2017 Apr;13(4):1353-1359. doi: 10.3892/etm.2017.4093. Epub 2017 Jan 31.

Isoquercetin activates the ERK1/2-Nrf2 pathway and protects against cerebral ischemia-reperfusion injury in vivo and in vitro

** Cell J. 2021 Aug;23(3):355-365. doi: 10.22074/cellj.2021.7116. Epub 2021 Jul 17.

Neuroprotective Effects of Isoquercetin: An In Vitro and In Vivo Study